Big Pharma

White House kills major drug pricing proposal

HHS Sec. Alex Azar
HHS Sec. Alex Azar. Photo: Sarah Silbiger/CQ Roll Call

A big part of the Trump administration's plan to lower drug prices is now dead, White House spokesman Judd Deere confirmed to Axios.

Why it matters: The administration is backing away from an effort to change the way money flows through federal health care programs — one of the most sweeping elements of its drug-pricing blueprint. That's bad news for pharma, and the move will put pressure on other parts of the administration's plan, which is also bad news for pharma.

Judge halts Trump administration rule requiring drug prices in TV ads

Health and Human Services Secretary Alex Azar.
Health and Human Services Secretary Alex Azar. Photo: Chip Somodevilla/Getty Images

A federal judge blocked the Trump administration Monday from implementing a new rule that would require pharmaceutical firms to include the wholesale prices of their drugs in TV advertising, Reuters reports.

The big picture: The Department of Health and Human Services (HHS) Secretary Alex Azar announced the new rule in May and it was due to take effect on Tuesday. But U.S. District Judge Amit Mehta in Washington, D.C., sided with drugmakers Merck & Co, Eli Lilly and Co and Amgen to halt the HHS rule.